이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Curis 미래 성장

Future 기준 확인 2/6

Curis은 연간 수입과 매출이 각각 5.5%와 37.4% 증가할 것으로 예상되고 EPS는 연간 39.5%만큼 증가할 것으로 예상됩니다.

주요 정보

0.8%

수익 성장률

36.0%

EPS 성장률

Biotechs 수익 성장	28.5%
매출 성장률	38.8%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	27 Sep 2024

최근 미래 성장 업데이트

Recent updates

Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%

Aug 07

Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet

Aug 05

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 03

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Dec 26

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Aug 18

Curis: Asymmetric Risk And Reward

Jul 17

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Mar 28

Checking In On Curis

Dec 15

Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

Dec 04

We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Aug 29

Curis Inc.: Revisiting CA-4948 After Q2 Update

Aug 25

Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Mar 19

Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year

Feb 17

Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition

Dec 23

Curis prices equity offering at $5.75/share

Dec 09

수익 및 매출 성장 예측

NasdaqCM:CRIS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	11	-57	-61	-53	6
12/31/2025	9	-49	-12	-44	6
12/31/2024	9	-48	-15	-44	6
6/30/2024	10	-48	-43	-43	N/A
3/31/2024	10	-48	-39	-39	N/A
12/31/2023	10	-47	-38	-38	N/A
9/30/2023	10	-47	-41	-41	N/A
6/30/2023	10	-48	-46	-45	N/A
3/31/2023	10	-52	-50	-50	N/A
12/31/2022	10	-57	-55	-54	N/A
9/30/2022	10	-59	-51	-50	N/A
6/30/2022	11	-57	-47	-47	N/A
3/31/2022	11	-52	-41	-41	N/A
12/31/2021	11	-45	-38	-38	N/A
9/30/2021	11	-39	-35	-35	N/A
6/30/2021	10	-34	-32	-31	N/A
3/31/2021	10	-30	-30	-30	N/A
12/31/2020	11	-30	-26	-26	N/A
9/30/2020	11	-31	-26	-26	N/A
6/30/2020	11	-31	-27	-26	N/A
3/31/2020	11	-32	-28	-28	N/A
12/31/2019	10	-32	-26	-26	N/A
9/30/2019	9	-29	-26	-26	N/A
6/30/2019	9	-30	-27	-27	N/A
3/31/2019	10	-32	-27	-27	N/A
12/31/2018	10	-33	-30	-30	N/A
9/30/2018	11	-35	-33	-33	N/A
6/30/2018	11	-43	-41	-41	N/A
3/31/2018	10	-48	N/A	-43	N/A
12/31/2017	10	-53	N/A	-48	N/A
9/30/2017	9	-57	N/A	-50	N/A
6/30/2017	8	-70	N/A	-41	N/A
3/31/2017	8	-67	N/A	-43	N/A
12/31/2016	8	-60	N/A	-36	N/A
9/30/2016	7	-63	N/A	-37	N/A
6/30/2016	8	-40	N/A	-34	N/A
3/31/2016	8	-37	N/A	-30	N/A
12/31/2015	8	-59	N/A	-30	N/A
9/30/2015	8	-51	N/A	-24	N/A
6/30/2015	7	-51	N/A	-21	N/A
3/31/2015	10	-45	N/A	-19	N/A
12/31/2014	10	-19	N/A	-17	N/A
9/30/2014	9	-17	N/A	-18	N/A
6/30/2014	15	-14	N/A	-15	N/A
3/31/2014	15	-13	N/A	-11	N/A
12/31/2013	15	-12	N/A	-10	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CRIS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CRIS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CRIS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CRIS 의 수익(연간 37.4% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: CRIS 의 수익(연간 37.4% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CRIS 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Curis 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Consensus revenue estimates increase by 14%

Price target decreased by 22% to US$77.40

Consensus EPS estimates upgraded to US$6.06 loss

Consensus revenue estimates increase by 28%, EPS downgraded

Price target increased by 18% to US$180

Consensus EPS estimates fall by 12%

Recent updates

New minor risk - Share price stability

Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%

Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet

New major risk - Negative shareholders equity

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 14%

Curis, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Curis, Inc. Announces Additional Data from Take Aim Leukemia Study

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Curis, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target decreased by 22% to US$77.40

Curis, Inc., Annual General Meeting, May 21, 2024

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Consensus EPS estimates upgraded to US$6.06 loss

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 28%, EPS downgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study

New major risk - Share price stability

Price target increased by 18% to US$180

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2023 Results on Aug 03, 2023

U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Price target increased to US$15.33

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$12.25

Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia Study

FDA Lifts Partial Clinical Hold on the Takeaim Lymphoma Study of Emavusertib of Curis, Inc

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Price target increased to US$17.67

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Curis: Asymmetric Risk And Reward

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc.(NasdaqGM:CRIS) dropped from Russell 3000E Growth Index

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

Consensus EPS estimates fall by 14%

Price target increased to US$15.75

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$14.20

Curis, Inc., Annual General Meeting, May 26, 2022

Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 Study

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Curis, Inc. Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations

Curis, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors